Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1937 1
1942 1
1945 4
1946 23
1947 19
1948 33
1949 26
1950 83
1951 105
1952 121
1953 119
1954 133
1955 113
1956 102
1957 147
1958 174
1959 180
1960 225
1961 241
1962 280
1963 370
1964 451
1965 363
1966 384
1967 579
1968 633
1969 786
1970 834
1971 868
1972 991
1973 1126
1974 1299
1975 1294
1976 1135
1977 1122
1978 1076
1979 1226
1980 1199
1981 1181
1982 1142
1983 1170
1984 1207
1985 1200
1986 1159
1987 1126
1988 1088
1989 1169
1990 1205
1991 1165
1992 1189
1993 1082
1994 1057
1995 1081
1996 970
1997 1001
1998 971
1999 1010
2000 1078
2001 1127
2002 1055
2003 1029
2004 1003
2005 1103
2006 1130
2007 1108
2008 1152
2009 1155
2010 1077
2011 1074
2012 1116
2013 1110
2014 1104
2015 1124
2016 1019
2017 1004
2018 1048
2019 1026
2020 1005
2021 903
2022 1027
2023 928
2024 478

Search Results

61,615 results

Results by year

Filters applied: . Clear all
Page 1
Luteal Phase Defects and Progesterone Supplementation.
Collins LC, Gatta LA, Dotters-Katz SK, Kuller JA, Schust DJ. Collins LC, et al. Obstet Gynecol Surv. 2024 Feb;79(2):122-128. doi: 10.1097/OGX.0000000000001242. Obstet Gynecol Surv. 2024. PMID: 38377455 Review.
Progesterone hypersensitivity: a cyclical history.
Brás-Cruz R, David F, Morais Ferreira R, Rosário C. Brás-Cruz R, et al. BMJ Case Rep. 2023 Nov 23;16(11):e256353. doi: 10.1136/bcr-2023-256353. BMJ Case Rep. 2023. PMID: 37996147
Addition of progesterone to feminizing gender-affirming hormone therapy in transgender individuals for breast development: a randomized controlled trial.
Dijkman BAM, Helder D, Boogers LS, Gieles NC, van Heesewijk JO, Slaa ST, Liberton NPTJ, Wiepjes CM, de Blok CJM, den Heijer M, Dreijerink KMA. Dijkman BAM, et al. BMC Pharmacol Toxicol. 2023 Dec 20;24(1):80. doi: 10.1186/s40360-023-00724-4. BMC Pharmacol Toxicol. 2023. PMID: 38124194 Free PMC article. Clinical Trial.
61,615 results
You have reached the last available page of results. Please see the User Guide for more information.